363
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Formation of Near-Infrared Fluorescent Nanoparticles for Medical Imaging

&
Pages 233-240 | Published online: 21 Jun 2011
 

Abstract

Aims: Indocyanine green (ICG) is a US FDA-approved near-infrared fluorescent, water-soluble dye used for diagnostics in vitro and in vivo. The aim of this study was to develop insoluble nanoparticles based on a cationic polymer, ICG and a targeting molecule. The particles are intended for oral administration in the colon, having fluorescence in near-infrared, thus enabling remote detection. Materials & methods: An aqueous dispersion of particles formed from Eudragit-RS by simple precipitation method possessing a mean size of approximately 100 nm and zeta potential of +16 mV was produced. Results: These particles are capable of binding both ICG and fluorescein isothiocyanate–IgG via noncovalent interactions. These composite particles retain the emission characteristics of the fluorescent precursors and also exhibit potential specific recognition ability. The particles were stable in intestinal fluid and are composed only of materials that are FDA approved. Conclusion: The nanoparticles may be suitable for in vivo imaging and therapy by oral delivery systems.

Financial & competing interests disclosure

This work was supported by the European Commission and the Integrated Project NACBO (contract number NMP4-CT-2004-500804) and the BMP magnet program. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This work was supported by the European Commission and the Integrated Project NACBO (contract number NMP4-CT-2004-500804) and the BMP magnet program. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.